Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2018-2023
Historical Year
2024-2032
Forecast Year
Leading Players in the North America Epilepsy Drugs Market
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
UCB SA
UCB (Union Chimique Belge) is a multinational biopharmaceutical company that specializes in the research and development of epilepsy treatments. In March 2022, the U.S. Food and Drug Administration (FDA) approved its drug (branded as Fintepla) to treat seizures associated with a rare form of childhood epilepsy, Lennox-Gastaut Syndrome (LGS).
Novartis AG
This Swiss multinational pharmaceutical corporation's drug asset TRILEPTAL is indicated for monotherapy or adjunctive therapy in adults to treat partial-onset seizures.
Pfizer Inc.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City and is actively involved in the development of epilepsy drugs. Its anti-epileptic medication Zarontin (ethosuximide) is used alone or in combination with other medicines to treat absence seizures in adults and children.
GSK Plc
The British multinational pharmaceutical and biotechnology company is known for its oral solution Keppra, indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization. It can be taken by adults and adolescents 16 years or above with newly diagnosed epilepsy.
Other players in the market include Abbott Laboratories, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd., Catalyst Pharmaceuticals Inc., and Alkem Laboratories Ltd.
North America Epilepsy Drugs Market Report Snapshots
North America Epilepsy Drugs Market Size
North America Epilepsy Drugs Market Analysis
North America Epilepsy Drugs Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4.30% during the forecast period of 2024-2032, driven by increased clinical trials and research initiatives to introduce novel anti-epileptic drugs in the region.
Rising healthcare expenditure and heightened patient awareness are fuelling the demand for the market.
One of the market significant trends is the rising entry of generic equivalents of epilepsy medications. For example, in December 2023, United States FDA approved Zydus Lifesciences Limited to manufacture and market a generic version of anti-epileptic medication, Lacosamide Tablets, in multiple strengths.
Based on the seizure type, the market is segmented into focal seizures, generalized seizures, and non-epileptic seizures, among others.
By drug generation, the market is divided into first generation drugs, second generation drugs, and third generation drugs.
By age group, the market is divided into pediatric and adult.
The market breakup by route of administration includes oral, nasal, injectable, and rectal, among others.
Distribution channels of the market are hospital pharmacies, drug stores and retail pharmacies, and online providers.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are UCB SA, Novartis AG, Pfizer Inc., GSK Plc, Abbott Laboratories, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd., Catalyst Pharmaceuticals Inc., and Alkem Laboratories Ltd.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
- Our Insights Store:
-
Industry Statistics
-
Procurement Insights
-
Consumer Insights
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124